Evidence map›Paper›PMID 37215670›Full record

SynthesisFrontiers in psychiatry2023

Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis.

Abdulrhman Khaity, Nada Mostafa Al-Dardery, Khaled Albakri, Omar A Abdelwahab, Mahmoud Tarek Hefnawy, Yaman A S Yousef, Ruaa E Taha, Sarya Swed, Wael Hafez, Rene Hurlemann and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. The Australian and New Zealand journal of psychiatry · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abdulrhman KhaityFaculty of Medicine, Elrazi University, Khartoum, Sudan.
Nada Mostafa Al-DarderyFaculty of Medicine, Fayoum University, Fayoum, Egypt.
Khaled AlbakriFaculty of Medicine, The Hashemite University, Zarqa, Jordan.
Omar A AbdelwahabFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Mahmoud Tarek HefnawyFaculty of Medicine, Zagazig University, Zagazig, Egypt.
Yaman A S YousefFaculty of Medicine, Elrazi University, Khartoum, Sudan.
Ruaa E TahaFaculty of Medicine, Khartoum University, Khartoum, Sudan.
Sarya SwedFaculty of Medicine, Aleppo University, Aleppo, Syria.
Wael HafezNMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates.
Rene HurlemannDepartment of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.
Mohamed E G ElsayedDepartment of Psychiatry, School of Medicine and Health Sciences, Carl von Ossietzky University Oldenburg, Oldenburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia. Methods: We searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean difference (MD) in the meta-analysis models using Review Manager (RevMan version 5.4). Results: Pooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,-4.46), Conclusion: Our analysis revealed that GLP-1 RA treatment is safe and effective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy of GLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended. Systematic review registration: http://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42022333040.

Indexed as

GLP-1 receptor agonistsmeta-analysisschizophreniasystematic reviewtreatment

Identifiers

PMID37215670
PMCPMC10196269

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.